Merck & Co.
AWARDS
NEWS
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
The U.S. Food and Drug Administration approved the anti-PD-1 therapy as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.
The DMC recommended the trial continue without changes in order to determine other dual-primary endpoints, such as event-free survival.
A new study identifies the risk factors that could help healthcare providers recognize patients being treated for diabetes who are most likely to have low blood sugar.
Merck will invest $680 million to build a manufacturing facility in Durham and expand an existing site in Wilson.
Despite the approval, Samsung Bioepis’ Hadlima will not be available in the U.S. until 2023, due to licensing deals with AbbVie, the maker of Humira.
JOBS
IN THE PRESS